Thank you, Bennett.
of sublingual equity second for between in we film of On the heels Anaphylm raise eventful for streamlined expand and our first buccal film had epinephrine Libervant FDA quarter, on gained successful X- X business We our the program, aged very growth progressed our quarter. to the diazepam to a X epilepsy group, continued patients years. and efforts age launch Libervant to focus X-year-old base our approval
Aquestive, action-packed usual days. was As XX an with this
and to to landscape with with competitive Starting reactions, epinephrine believe the only potential including of attributes. for I such carrying momentum oral ease focused life than When We Anaphylm, the of Anaphylm be its past build. easily have On our Anaphylm, patient's look the these anaphylaxis. earnings I on fits optimistic as more treatment and ever first ease for differentiated product due product the allergic the daily remain some severe attributes I calls, highly continues at important use. to of within of
differentiation. on expand of me let area additional Today, an
Let's world. about of in the real products durability talk the rescue
effective may in of up temperatures. is on soccer that main strict are the high period to of field longer devices in as form medical instructions a left time. an be they reasons made You see Products degradation largely come if water. extended summer heat no one storage have such EpiPens for are subject approved they real-world of water epinephrine such of like are conditions auto-injectors in largely liquid and as composed That
the that of is water. estimate formulation EpiPen XX% We
is about composed of X% Only Anaphylm. product Anaphylm the water. think Now of
potential the of oral potential over exposure. long products has As durations films has low remain after do to we potential It content different. to to spectrum in conditions, not freezing broad Anaphylm's are X even the real-world product or which a decades, our water pipeline be heat this the have we stable category. It by it still with other means in the other of temperatures. work means last believe means work seen matched Anaphylm has in can Anaphylm existing any
our to progress. turning Now development
We These X for and top line study. cases, FDA we positive. the as temperature/pH supportive study data necessary engaging completed studies meeting. in a X self-administration In are publicly, already have was of both the successfully the our have shared pre-NDA
study, currently third clinic. allergen is our challenge study, the in The oral
needed advancing our late completion are or of quarter fourth in We the year. expect the in and quarter for enrollment third study this patients study of early the of the the
We has continue immediately to the we a holding quarter meeting Once study pediatric starting study completed, pre-NDA in file pediatric the anticipate and fourth afterwards. our NDA. our will
of December quarter or At first Based FDA and launch complete the our of in the this the time, the XXXX in we a quarter submission first of remains approval, timing XXXX submission end for our in begin to on XXXX. expect full NDA at unchanged.
focused activities Our physicians, the experienced and advocacy track. place increasing We on have now leadership in over community. affairs awareness and for both among The team commercial very Anaphylm. remain commercial efforts on medical payers is our launch
to and horizon, fits no the caregivers. back a health There's of universe, are and are like or of on needle, stakeholder Anaphylm, you patients. carrying needs the rate the field. there the is to is wallet hearing nothing Anaphylm other whether patients enough for Anaphylm beach no may significant be providers, on durable phone or the though activities while go, your potentially Anaphylm in carry is easily you withstand all a case. devices for of device, the need the Even soccer medical oral answer improving patients, to no care to administration. the headed everywhere carry alternative real-life unmet and keep Across this is address we that entire their easy
such and including asthma. dermatitis severe atopic as allergic highly is Anaphylm Anaphylm suggests differentiated data for by remains rescue disrupt positively poised Our anaphylaxis. to not congestion, impacted and allergic comorbid diseases treatment reactions,
have closer distribute and filing had inbound launch, interested we from companies to get helping inquiries Anaphylm. we As us in multiple
is of approved patients goal to Our if maximize Anaphylm immediately the by all to the distribution FDA.
continue year, can the if augmented Over by we our and examine commercial next utilizing efforts to will of sales be companies. other platforms distribution the
of to Speaking commercialization, let's turn Libervant.
expanding are focused our launch to X- X-year-old group. on We now in the Libervant age
value months, last and received the on few patients Libervant Over significant their benefits caregivers. we and feedback to offers the have
children's information This feedback major seeking institutions includes across Libervant. outreach country on are proactively for who the
while through the fourth to capabilities and commercial coverage continuously We distribution place national in Medicaid our retail October expect improving quarter. have by X,
a team expand representatives to will of We in national sales XX late QX.
result our in the single-digit We for of in Libervant believe $X team millions group somewhere and age to neighborhood million. expanding sales XXXX X-year-old be cash will to burn XXXX top in X- minimal for generate line in the in revenue will
While term, Anaphylm in exclusivity. drug the on if in that in approved, may and as a seem the XXXX, launch orphan there modest prepare Libervant benefit for full significant is a our of short company to competitor's launch we the expiration XXXX
the we in to as million long-term look in We see $XXX in weeks X- group a for to and annual X-year-old sales over with expansion Libervant sales, net forward peak potential age continue to the our the brand to come.
epinephrine platform. our Adrenaverse Now let's prodrug to turn
the potential to promised, investor community preparing we share Adrenaverse. of future with on more As the pipeline are
Anaphylm platform out believe products recall, will additional may We you this platform. come technology. there of As born major was our that are from Adrenaverse
position our our to propel how scientific thinking, from work next Investor behind of an Anaphylm the has and business. science that few months, the helped intellectual platform, exciting products done. Day This an the property In could outline we we have our potential Adrenaverse will is unique hold the part arise our
as our U.S.-based will have provide details existing completed the of for well This Aquestive's Exservan longer eliminated negligible. of review focusing riluzole business, revenue Ernie more XXXX, no film. our a base on on unprofitable we as Finally, our terminating was oral moment. on distribution In strategic includes from our in partnership and Exservan relationships. collaborations revenue our China
with the allow Libervant on base for approved. if launch while Anaphylm, the responsible to also Indivior, as focus executives of Hypera, preparing SYMPAZAN our such and higher and with Suboxone Eliminating distractions Zambon, business of Assertio for these with Emylif volumes with will products Ondif
conclusion, a we incredible growth continue company be with to In potential.
lead end filing. the Our nearing it's believe pipeline its of is program, anaphylaxis, from Anaphylm allergic cycle, severe reactions, including development we months away and for only
long-term Our commercial begin still a product, opportunity commercialization to low-risk, Libervant, potential. environment, affords in low-cost significant retaining us while the
meaningful us years come, to Adrenaverse our generate be programs a base continues to our intellectual unique for part meaningful can that gives of platform position business property and story. a Our
over to I that, the With call Ernie. will turn
